98%
921
2 minutes
20
Human immunodeficiency virus (HIV) vaccines have not been successful in clinical trials. Dimeric IgA (dIgA) in the form of secretory IgA is the most abundant antibody class in mucosal tissues, making dIgA a prime candidate for potential HIV vaccines. We coupled Positron Emission Tomography (PET) imaging and fluorescent microscopy of 64Cu-labeled, photoactivatable-GFP HIV (PA-GFP-BaL) and fluorescently labeled dIgA to determine how dIgA antibodies influence virus interaction with mucosal barriers and viral penetration in colorectal tissue. Our results show that HIV virions rapidly disseminate throughout the colon two hours after exposure. The presence of dIgA resulted in an increase in virions and penetration depth in the transverse colon. Moreover, virions were found in the mesenteric lymph nodes two hours after viral exposure, and the presence of dIgA led to an increase in virions in mesenteric lymph nodes. Taken together, these technologies enable in vivo and in situ visualization of antibody-virus interactions and detailed investigations of early events in HIV infection.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8195437 | PMC |
http://dx.doi.org/10.1371/journal.ppat.1009632 | DOI Listing |
JMIR Res Protoc
September 2025
Guangxi Key Laboratory of AIDS Prevention and Treatment, School of Public Health & Life Science Institute, Guangxi Medical University, Nanning, China.
Background: The 23-valent pneumococcal polysaccharide vaccine reduces the risk of pneumonia among adults by 38% to 46%. However, only a few older adults in resource-limited areas of China have received the pneumococcal vaccination. Pay-it-forward is a social innovation that offers participants free or subsidized health services and a community-engaged message, with an opportunity to donate to support subsequent recipients.
View Article and Find Full Text PDFJ Med Virol
September 2025
Department of Interdisciplinary Oncology, School of Medicine, Stanley S. Scott Cancer Center of Excellence, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA.
Kaposi sarcoma (KS) remains a global health concern. In sub-Saharan Africa, where there is a high burden of HIV-1 infection, there is also a high prevalence of infection by the etiologic agent of KS, the KS-associated herpesvirus (KSHV). Despite the successes of antiretroviral treatment (ART), the burden of KS and other KSHV-associated malignancies among people living with HIV under ART remained high, stressing the need for a greater understanding of the immune response against KSHV infection.
View Article and Find Full Text PDFCurr HIV Res
September 2025
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA.
Newborns represent only 1% of the population. Yet, HIV vertical transmissions represent 10% of all new infections globally, even though antiretroviral therapy (ART) has been shown to reduce the risk of vertical transmission to less than 2%. While vaccines still represent the most efficient and cost-effective intervention to eradicate new infections, HIV immunogens that can effectively elicit broad-spectrum protection are still at least a decade away.
View Article and Find Full Text PDFHum Vaccin Immunother
December 2025
Department Obstetrics & Gynaecology, University of Toronto, Toronto, Canada.
HPV vaccination in adults provides opportunities for individuals who were previously ineligible, or who missed vaccination as adolescents, thereby reducing HPV-related disease burden. This targeted literature review summarizes the HPV vaccination recommendations and guidelines by National Immunization Technical Advisory Groups and professional societies, and public funded programs for adults. Of the 152 jurisdictions examined, 62 offered HPV vaccination recommendations for general adults.
View Article and Find Full Text PDFFront Cell Infect Microbiol
September 2025
Infectious Diseases and Oncology Research Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
The escalating cancer burden in Sub-Saharan Africa (SSA), with projected doubling of incidence and mortality by 2040, necessitates innovative, cost-effective strategies for prevention, diagnosis, and treatment. While known infectious triggers like HPV, hepatitis viruses, and account for an estimated 28.7% of cancers in SSA, the full scope of microbially-mediated oncogenesis remains underexplored.
View Article and Find Full Text PDF